Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 8;5(1):55-65.
doi: 10.1002/lio2.346. eCollection 2020 Feb.

Organ preservation following radiation therapy and concurrent intra-arterial low dose cisplatin infusion for advanced T2 and T3 laryngeal cancer: Long-term clinical results from a pilot study

Takeharu Ono  1 , Norimitsu Tanaka  2 , Syuichi Tanoue  2 , Yusaku Miyata  2 , Koichiro Muraki  2 , Chiyoko Tsuji  2 , Etsuyo Ogo  2 , Takeichiro Aso  1 , Shun-Ichi Chitose  1 , Buichiro Shin  1 , Tatsuyuki Kakuma  3 , Hidehiro Etoh  2 , Chikayuki Hattori  2 , Toshi Abe  2 , Hirohito Umeno  1
Affiliations

Organ preservation following radiation therapy and concurrent intra-arterial low dose cisplatin infusion for advanced T2 and T3 laryngeal cancer: Long-term clinical results from a pilot study

Takeharu Ono et al. Laryngoscope Investig Otolaryngol. .

Abstract

Background: This pilot study evaluated the long-term outcomes of patients with advanced T2 or T3 squamous cell carcinoma of the larynx (SCC-L) who were treated with selective intra-arterial cisplatin and concomitant radiotherapy (RADPLAT).

Methods: We retrospectively investigated the data of 49 patients with advanced T2 or T3 SCC-L who received a RADPLAT regimen with low-dose cisplatin.

Results: The 5-year locoregional control, disease-specific survival, and overall survival rates were 83.3%, 88.1%, and 82.6%, respectively, while the 5-year freedom from laryngectomy, laryngectomy-free survival, and laryngo-esophageal dysfunction-free survival rates were 89.6%, 79.4%, and 77.1%, respectively. The incidences of grade 3-4 hematologic and nonhematologic toxicities were 18% and 6%, respectively. Although two patients (4%) developed late toxicities within 5 years following RADPLAT, no other events were noted beyond 5 years.

Conclusion: This pilot study demonstrated that RADPLAT is feasible and safe and yielded favorable survival outcomes and functional laryngeal preservation in patients with advanced T2 or T3 SCC-L.

Level of evidence: 3.

Keywords: concurrent intra‐arterial low dose cisplatin infusion; laryngeal preservation; late toxicity; radiation therapy; squamous cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Schema of eligibility and response data to selective radiotherapy and concomitant intra‐arterial cisplatin (RADPLAT). CDDP, cisplatin; CR, complete response; PD, progressive disease
Figure 2
Figure 2
Clinical outcomes after RADPLAT. Kaplan‐Meier curves of LRC, DSS, OS, FFL, LFS, and LEDFS in patients with all SCC‐L. DSS, disease‐specific survival; FFL, freedom from laryngectomy; LEDFS, laryngo‐esophageal dysfunction‐free survival; LFS, laryngectomy‐free survival; LRC, locoregional control; OS, overall survival; SCC‐L, squamous cell carcinoma of the larynx
Figure 3
Figure 3
Kaplan‐Meier curves of LRC, DSS, OS in patients with SCC‐L according to, A‐C, T stage and, D‐F, clinical stage. DSS, disease‐specific survival; LRC, locoregional control; OS, overall survival; SCC‐L, squamous cell carcinoma of the larynx
Figure 4
Figure 4
Kaplan‐Meier curves of FFL, LFS, and LEDFS in patients with SCC‐L according to, A‐C, T stage and, D‐F, clinical stage. FFL, freedom from laryngectomy; LEDFS, laryngo‐esophageal dysfunction‐free survival; LFS, laryngectomy‐free survival; SCC‐L, squamous cell carcinoma of the larynx
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Steuer CE, El‐Deiry M, Parks JR, Higgins KA, Saba NF. An update on larynx cancer. CA Cancer J Clin. 2017;67:31‐50. - PubMed
    1. Caudell JJ, Carroll WR, Spencer SA, Bonner JA. Examination of laryngoesophageal dysfunction‐free survival as an endpoint in nonsurgical treatment of squamous cell carcinomas of the larynx and hypopharynx. Cancer. 2011;117:4447‐4451. - PubMed
    1. Adelstein DJ, Lavertu P, Saxton JP, et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer. 2000;88:876‐883. - PubMed
    1. Bonner J, Giralt J, Harari P, et al. Cetuximab and radiotherapy in laryngeal preservation for cancers of the larynx and hypopharynx: a secondary analysis of a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2016;142:842‐849. - PMC - PubMed
    1. Megwalu UC, Sikora AG. Survival outcomes in advanced laryngeal cancer. JAMA Otolaryngol Head Neck Surg. 2014;140:855‐860. - PubMed

LinkOut - more resources